Fig. 1
From: Risks and management of hypertension in cancer patients undergoing targeted therapy: a review
Mechanism of hypertension secondary to targeted therapy. Different targeted anti-cancer agents (brown color) can have a variety of distinct effects on the development of hypertension due to increased systematic vascular resistance and cardiac output. VEGF, vascular endothelial growth factor; NO, nitric oxide; ET-1, endothelin-1; BP, blood pressure; CO, cardiac output; SVR, systematic resistance; ACTH, adrenal cortical trophic hormone